BETTY MOORE: Open Payments
NPI 1366746257 · STEVENSVILLE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 34 payments from 11 companies in 2025. Trend: 2023 $70 · 2024 $730 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| ABBVIE INC. | 5 | $113 |
| Regeneron Healthcare Solutions, Inc. | 2 | $109 |
| Lilly USA, LLC | 4 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| PFIZER INC. | 4 | $75 |
| Gilead Sciences, Inc. | 3 | $69 |
| Novo Nordisk Inc | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
Products named: DUPIXENT, OMVOH, XIFAXAN, XELJANZ, GATTEX, Wegovy, ENTYVIO, SKYRIZI.
Industry payments across MI — which companies pay providers there.
